FloraGLO^® Lutein for Maternal & Infant Health

FloraGLO® Lutein plays a crucial role in supporting maternal nutrition and infant development, particularly benefiting eye and brain health during crucial stages of growth.^1-4

FloraGLO® Lutein offers significant benefits for both mothers and infants:

• Maternal Nutrition: It is a safe¹⁰ and essential^11-12 nutrient during pregnancy, known for its antioxidant properties that protect cells from oxidative stress and inflammation.⁸
• Infant Development: Lutein is naturally found in cord blood and breast milk⁵

During pregnancy and breastfeeding, maintaining adequate lutein levels is critical as they naturally decline with the duration of breastfeeding⁶, influenced by maternal dietary intake.⁹

For infants, FloraGLO® Lutein supports:

• Eye & Brain Development: Serving as an antioxidant and blue light filter⁷, it plays a vital role in protecting the developing retina and neural tissues from environmental stressors.^8,18-26

Incorporating FloraGLO® Lutein into prenatal vitamins and fortified infant formulas ensures optimal maternal and infant nutrition. Its efficacy is backed by extensive research, making it a trusted choice globally for maternal and infant health.

Resources

Want To Learn More About FloraGLO Lutein?

Fill out the form below and a Kemin representative will be in touch shortly.

Recommended use: a dose of = 10 mg FloraGLO® Lutein and 2 mg OPTISHARP™ Natural Zeaxanthin is considered efficacious.

*Kemin has a blue light patent covering three conditions for people of all ages; presbyopia, hyperopia, and astigmatism.

OPTISHARP™ Natural is a Registered Trademark of DSM Nutritional Products Ltd.

OPTISHARP™ Natural is made with ZeaOne(R) from KEMIN. ZeaOne is a [registered] trademark of KEMIN Industries, Inc. 

These statements have not been evaluated by the US Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.

The information on this webpage is a business-to-business information and not intended for the final consumer. Certain statements may not be applicable in all geographical regions. Product labeling and associated claims differs based upon government requirements and country or region specific information should also be considered when labeling or advertising to final consumers.

This web page and its associated brochures and other documents do not constitute or provide scientific or medical advice, diagnosis, or treatment and are distributed without warranty of any kind, either expressly or implied. This web page, its title or contents and associated brochures and other documents do not in any way make recommendations for health or marketing claims by the reader. Country and region specific regulations should be considered in this regard. Each claim or statement about the effectiveness of Kemin products and/or each claim or statement comparing the effectiveness of Kemin products to the effectiveness of other products is expressly limited to the United States, unless otherwise disclosed on the Kemin websites.

References:

1. Wooten BR, Hammond BR. Macular pigment: Influences on visual acuity and visibility. Prog Retin Eye Res. 2002;21(2):225–40.
2. Krinsky NI, Landrum JT, Bone RA. Biologic mechanism of the protective role of Lutein and Zeaxanthin in the Eye. Annu Rev Nutr. 2003;23:171–201.
3. Kritchevsky SB, Bush AJ, Pahor M, Gross MD. Serum carotenoids and markers of inflammation in nonsmokers. Am J Epidemiol. 2000;152(11):1065–71.
4. Gruszecki WI, Strzałka K. Carotenoids as modulators of lipid membrane physical properties. Biochim Biophys Acta - Mol Basis Dis. 2005;1740(2):108–15
5. Sun, H. et al. Carotenoid profile in breast milk and maternal and cord plasma: A longitudinal study in southwest China. Br. J. Nutr. Jan 8, 1–7 (2021).
6. Schweigert, F. J., Bathe, K., Chen, F., Buscher, U., and Dudenhausen, J. W. (2004) Effect of the stage of lactation in humans on carotenoid levels in milk, blood plasma and plasma lipoprotein fractions, Eur J Nutr 43, 39-44.
7. Hardy, P., Dumont, I., Bhattacharya, M., Hou, X., Lachapelle, P., Varma, D. R., and Chemtob, S. (2000) Oxidants, nitric oxide and prostanoids in the developing ocular vasculature: a basis for ischemic retinopathy, Cardiovasc Res 47, 489-509.
8. Kim, S. R., Nakanishi, K., Itagaki, Y., and Sparrow, J. R. (2006) Photooxidation of A2-PE, a photoreceptor outer segment fluorophore, and protection by lutein and zeaxanthin, Exp Eye Res 82, 828-839.
9. Cena, H., Castellazzi, A. M., Pietri, A., Roggi, C., and Turconi, G. (2009) Lutein concentration in human milk during early lactation and its relationship with dietary lutein intake, Public Health Nutr 12, 1878-1884.
10. U.S. Food & Drug Administration, 2004. GRAS Notice Inventory, GRN No. 140, 221 and 390.
11. Hardy, P., Dumont, I., Bhattacharya, M., Hou, X., Lachapelle, P., Varma, D. R., and Chemtob, S. (2000) Oxidants, nitric oxide and prostanoids in the developing ocular vasculature: a basis for ischemic retinopathy, Cardiovasc Res 47, 489-509.
12. Woodall, A. A., Britton, G., and Jackson, M. J. (1997) Carotenoids and protection of phospholipids in solution or in liposomes against oxidation by peroxyl radicals: relationship between carotenoid structure and protective ability, Biochim Biophys Acta 1336, 575-586.
13. Rubin, L. P., Chan, G. M., Barrett-Reis, B. M., Fulton, A. B., Hansen, R. M., Ashmeade, T. L., Oliver, J. S., Mackey, A. D., Dimmit, R. A., Hartmann, E. E., and Adamkin, D. H. (2012) Effect of carotenoid supplementation on plasma carotenoids, inflammation and visual development in preterm infants, J Perinatol 32, 418-424.
14. Romagnoli, C., Giannantonio, C., Cota, F., Papacci, P., Vento, G., Valente, E., Purcaro, V., and Costa, S. (2011) A prospective, randomized, double blind study comparing lutein to placebo for reducing occurrence and severity of retinopathy of prematurity, J Matern Fetal Neonatal Med 24 Suppl 1, 147-150.
15. Romagnoli, C., Tirone, C., Persichilli, S., Gervasoni, J., Zuppi, C., Barone, G., and Zecca, E. (2010) Lutein absorption in premature infants, Eur J Clin Nutr 64, 760-761.
16. Bettler, J., Zimmer, J. P., Neuringer, M., and DeRusso, P. A. (2010) Serum lutein concentrations in healthy term infants fed human milk or infant formula with lutein, Eur J Nutr 49, 45-51.
17. Mackey, A. D., Albrecht, D., Oliver, J., Williams, T., Long, A. C., and Price, P. T. (2012) Plasma carotenoid concentrations of infants are increased by feeding a milk-based infant formula supplemented with carotenoids, J Sci Food Agric.
18. Dillon, J., Zheng, L., Merriam, J. C., and Gaillard, E. R. (2004) Transmission of light to the aging human retina: possible implications for age related macular degeneration, Exp Eye Res 79, 753-759.
19. Feeney-Burns, L., Hilderbrand, E. S., and Eldridge, S. (1984) Aging human RPE: morphometric analysis of macular, equatorial, and peripheral cells, Invest Ophthalmol Vis Sci 25, 195-200.
20. Wing, G. L., Blanchard, G. C., and Weiter, J. J. (1978) The topography and age relationship of lipofuscin concentration in the retinal pigment epithelium, Invest Ophthalmol Vis Sci 17, 601-607.
21. Sparrow, J. R., and Boulton, M. (2005) RPE lipofuscin and its role in retinal pathobiology, Exp Eye Res 80, 595-606.
22. Sparrow, J. R., Fishkin, N., Zhou, J., Cai, B., Jang, Y. P., Krane, S., Itagaki, Y., and Nakanishi, K. (2003) A2E, a byproduct of the visual cycle, Vision Res 43, 2983-2990.
23. Wu, Y., Yanase, E., Feng, X., Siegel, M. M., and Sparrow, J. R. (2010) Structural characterization of bisretinoid A2E photocleavage products and implications for age-related macular degeneration, Proc Natl Acad Sci U S A 107, 7275-7280.
24. Hardy, P., Dumont, I., Bhattacharya, M., Hou, X., Lachapelle, P., Varma, D. R., and Chemtob, S. (2000) Oxidants, nitric oxide and prostanoids in the developing ocular vasculature: a basis for ischemic retinopathy, Cardiovasc Res 47, 489-509.
25. Abramov, I., Gordon, J., Hendrickson, A., Hainline, L., Dobson, V., and LaBossiere, E. (1982) The retina of the newborn human infant, Science 217, 265-267.
26. Yuodelis, C., and Hendrickson, A. (1986) A qualitative and quantitative analysis of the human fovea during development, Vision Res 26, 847-855.